|
|
Article: Neurocrine Biosciences Completes Enrollment in Chronic and Transient Phase II Insomnia Clinical Trials.
- Article from:
- PR Newswire
- Article date:
- May 10, 2001
|
Copyright informationCOPYRIGHT 2001 PR Newswire Association, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Neurocrine Expected to Initiate Phase III Pivotal Clinical Trials
SAN DIEGO, May 10 /PRNewswire/ --
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the Company has completed enrollment in its Phase II transient and chronic insomnia clinical trials with NBI-34060 and is expected to report results at the end of June 2001. In addition, the company reported the initiation of multiple dose ranging and efficacy based clinical trials for its immediate and modified release formulations, the results of which will be released during the year. Based on the results of these studies, the company is expecting to move into multiple Phase III clinical ...
Related newspaper, magazine, and journal articles:
|